S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
NASDAQ:NBTX

Nanobiotix Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$16.67
-0.11 (-0.66 %)
(As of 03/2/2021 04:00 PM ET)
Add
Compare
Today's Range
$16.67
Now: $16.67
$16.81
50-Day Range N/A
52-Week Range N/A
Volume1,023 shs
Average Volume38,941 shs
Market Capitalization$555.78 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Nanobiotix (NASDAQ:NBTX) Vs. CGEM, SBTX, VOR, BCAB, GRCL, and ITOS

Should you be buying NBTX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Nanobiotix, including Cullinan Management (CGEM), Silverback Therapeutics (SBTX), Vor Biopharma (VOR), BioAtla (BCAB), Gracell Biotechnologies (GRCL), and iTeos Therapeutics (ITOS).

Cullinan Management (NASDAQ:CGEM) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Cullinan Management and Nanobiotix, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Management01302.75
Nanobiotix00203.00

Cullinan Management presently has a consensus price target of $48.00, indicating a potential downside of 7.82%. Given Cullinan Management's higher probable upside, analysts plainly believe Cullinan Management is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Cullinan Management and Nanobiotix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan ManagementN/AN/AN/AN/AN/A
NanobiotixN/AN/AN/AN/AN/A

Profitability

This table compares Cullinan Management and Nanobiotix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan ManagementN/AN/AN/A
NanobiotixN/AN/AN/A

Summary

Cullinan Management beats Nanobiotix on 2 of the 3 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and Silverback Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nanobiotix00203.00
Silverback Therapeutics00403.00

Silverback Therapeutics has a consensus target price of $46.25, indicating a potential downside of 12.97%. Given Silverback Therapeutics' higher probable upside, analysts plainly believe Silverback Therapeutics is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Nanobiotix and Silverback Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanobiotixN/AN/AN/AN/AN/A
Silverback TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Nanobiotix and Silverback Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanobiotixN/AN/AN/A
Silverback TherapeuticsN/AN/AN/A

Summary

Silverback Therapeutics beats Nanobiotix on 2 of the 2 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and Vor Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nanobiotix00203.00
Vor Biopharma10102.00

Given Vor Biopharma's higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Nanobiotix and Vor Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanobiotixN/AN/AN/AN/AN/A
Vor BiopharmaN/AN/AN/AN/AN/A

Profitability

This table compares Nanobiotix and Vor Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanobiotixN/AN/AN/A
Vor BiopharmaN/AN/AN/A

Summary

Nanobiotix beats Vor Biopharma on 2 of the 3 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and BioAtla, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nanobiotix00203.00
BioAtla00403.00

BioAtla has a consensus target price of $48.00, indicating a potential downside of 7.01%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Nanobiotix and BioAtla's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanobiotixN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Profitability

This table compares Nanobiotix and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanobiotixN/AN/AN/A
BioAtlaN/AN/AN/A

Summary

BioAtla beats Nanobiotix on 2 of the 2 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and Gracell Biotechnologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nanobiotix00203.00
Gracell Biotechnologies00403.00

Gracell Biotechnologies has a consensus target price of $34.50, indicating a potential upside of 44.17%. Given Gracell Biotechnologies' higher probable upside, analysts plainly believe Gracell Biotechnologies is more favorable than Nanobiotix.

Earnings and Valuation

This table compares Nanobiotix and Gracell Biotechnologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanobiotixN/AN/AN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/AN/AN/A

Profitability

This table compares Nanobiotix and Gracell Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanobiotixN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/A

Summary

Gracell Biotechnologies beats Nanobiotix on 2 of the 2 factors compared between the two stocks.

Nanobiotix (NASDAQ:NBTX) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Nanobiotix and iTeos Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanobiotixN/AN/AN/AN/AN/A
iTeos TherapeuticsN/AN/AN/AN/AN/A

Institutional & Insider Ownership

71.1% of iTeos Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Nanobiotix and iTeos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanobiotixN/AN/AN/A
iTeos TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Nanobiotix and iTeos Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nanobiotix00203.00
iTeos Therapeutics00503.00

iTeos Therapeutics has a consensus target price of $43.40, indicating a potential downside of 1.52%. Given iTeos Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Nanobiotix.

Summary

iTeos Therapeutics beats Nanobiotix on 3 of the 3 factors compared between the two stocks.


Nanobiotix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CGEM
Cullinan Management
1.0$52.29-7.5%$2.00 billionN/A0.00News Coverage
Gap Up
SBTX
Silverback Therapeutics
1.8$52.80-1.5%$1.72 billionN/A0.00Increase in Short Interest
VOR
Vor Biopharma
0.8$42.59-12.7%$1.71 billionN/A0.00Analyst Report
News Coverage
Gap Up
BCAB
BioAtla
1.6$51.85-0.9%$1.68 billionN/A0.00Increase in Short Interest
GRCL
Gracell Biotechnologies
1.7$24.10-3.6%$1.64 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.6$44.20-3.9%$1.49 billionN/A0.00Upcoming Earnings
News Coverage
Gap Down
KNTE
Kinnate Biopharma
2.0$33.17-3.4%$1.42 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$35.91-0.9%$1.41 billionN/A0.00
PHVS
Pharvaris
0.8$38.75-1.2%$1.25 billionN/A0.00Analyst Report
News Coverage
Gap Up
FDMT
4D Molecular Therapeutics
0.9$42.68-1.0%$1.09 billionN/A0.00Increase in Short Interest
PHAR
Pharming Group
0.0$13.46-1.5%$871.59 millionN/A0.00Increase in Short Interest
News Coverage
SGTX
Sigilon Therapeutics
1.9$29.39-2.2%$867.66 millionN/A0.00Increase in Short Interest
Gap Down
LABP
Landos Biopharma
1.1$14.37-13.2%$636.79 millionN/A0.00Analyst Report
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
1.7$15.44-2.0%$604.69 millionN/A0.00
TERN
Terns Pharmaceuticals
1.3$24.08-2.3%$590.67 millionN/A0.00Analyst Report
News Coverage
ANGN
Angion Biomedica
1.0$20.90-4.7%$572.12 millionN/A0.00Analyst Report
News Coverage
Gap Down
NEXI
NexImmune
0.3$23.14-5.3%$558.39 millionN/A0.00
SNSE
Sensei Biotherapeutics
1.3$16.11-5.5%$502.49 millionN/A0.00Analyst Report
News Coverage
DBTX
Decibel Therapeutics
0.3$18.07-0.4%$441.08 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.2$7.35-3.5%$388.91 millionN/A-3.91
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$9.58-2.4%$352.98 millionN/A-3.79News Coverage
GMTX
FS Development
1.0$16.01-2.6%$242.35 millionN/A0.00Analyst Report
News Coverage
IPA
ImmunoPrecise Antibodies
0.0$14.00-5.5%$222.38 millionN/A0.00Decrease in Short Interest
NUVB
Nuvation Bio
0.0$10.86-2.7%$195.08 millionN/A0.00
ANVS
Annovis Bio
0.0$28.37-5.5%$185.08 millionN/A0.00
VINC
Vincerx Pharma
1.0$20.65-6.8%$157.86 millionN/A0.00Increase in Short Interest
EVAX
Evaxion Biotech A/S
1.0$7.75-8.6%$148.79 millionN/A0.00Analyst Report
News Coverage
Gap Down
LGVN
Longeveron
0.3$8.19-3.5%$147.79 millionN/A0.00Gap Down
IKT
Inhibikase Therapeutics
0.0$6.70-0.1%$67.44 millionN/A0.00News Coverage
VIRI
Virios Therapeutics
1.3$6.27-4.5%$51.30 millionN/A0.00Gap Up
VLON
Vallon Pharmaceuticals
0.3$5.98-3.7%$41.89 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.52-9.4%$2.97 millionN/A0.00News Coverage
Gap Up
ADTX
ADiTx Therapeutics
1.0$3.22-0.0%$0.00N/A0.00Decrease in Short Interest
CBDC
Apotheca Biosciences
0.4$0.03-33.3%$0.00N/A0.00Gap Down
CDMOP
Avid Bioservices
0.3$30.95-1.5%$0.00N/A0.00Increase in Short Interest
SCPS
Scopus BioPharma
1.4$8.88-0.8%$0.00N/A0.00Decrease in Short Interest
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.